|
1
|
Devesa SS, Blot WJ and Fraumeni JF Jr.:
Changing patterns in the incidence of esophageal and gastric
carcinoma in the United States. Cancer. 83:2049–2053. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuhajda FP: Fatty acid synthase and
cancer: New application of an old pathway. Cancer Res.
66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Notarnicola M, Tutino V, Calvani M, et al:
Trastuzumab in combination with chemotherapy versus chemotherapy
alone for treatment of HER2-positive advanced gastric or
gastro-oesophageal junction cancer (ToGA):A phase3, open-label,
randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ito T, Sako K, Maekawa H, et al: Elevated
levels of serum fatty acid synthase in patients with gastric
carcinoma. Oncol Lett. 7:616–620. 2014.PubMed/NCBI
|
|
5
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weiss L, Hoffmann GE, Schreiber R, et al:
Fatty-acid biosynthesis in man, a pathway of minor importance.
Purification, optimal assay conditions, and organ distribution of
fatty-acid synthase. Biol Chem Hoppe Seyler. 367:905–912. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wagle S, Bui A, Ballard Pl, et al:
Hormonal regulation and cellular localization of fatty acid
synthase in human fetal lung. Am J Physiol. 227:L381–L390.
1999.
|
|
8
|
Kusakabe T, Maeda M, Hoshi N, et al: Fatty
acid synthase is expressed mainly in adult hormone-sensitive cells
or cells with high lipid metabolism and in proliferating fetal
cells. J Histochem Cytochem. 48:613–622. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pizer ES, Kurman RJ, Pasternack GR and
Kuhjada FP: Expression of fatty acid synthase is closely linked to
prolieration and stromal decidualization in cycling endometrium.
Int J Gynecol Pathol. 16:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuhajada FP: Fatty acid synathase and
cancer: New application of an old pathway. Cancer Res.
66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abramson HN: The lipogenesis pathway as a
cancer target. J Med Chem. 54:5615–5638. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tischler V, Fritzsche FR, Gerhardt J, et
al: Comparison of the diagnostic value of fatty acid synthase
(FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic
cancer tissue marker. Histopathology. 56:811–815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nguyen PL, Ma J, Chavarro JE, et al: Fatty
acid synthase polymorphisms, tumor expression, body mass index,
prostate cancer risk, and survival. J Clin Oncol. 28:3958–3964.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heo CK, Woo MK, Yu DY, et al:
Identification of autoantibody against fatty acid synthase in
hepatocellular carcinoma mouse model and its application to
diagnosis of HCC. Int J Oncol. 36:1453–1459. 2010.PubMed/NCBI
|
|
15
|
Ishimura N, Amano Y, SanchezSiles AA, et
al: Fatty acid synthase expression in Barrett's esophagus:
Implications for carcinogenesis. J Clin Gastroenterol. 45:665–672.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Furuta E, Pai SK, Zhan R, et al: Fatty
acid synthase gene is up-regulated by hypoxia via activation of Akt
and sterol regulatory element binding protein-1. Cancer Res.
68:1003–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calvisi DF, Wang C, Ho C, et al: Increased
lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes
development of human hepatocellular carcinoma. Gastroenterology.
140:1071–1083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim K, Kim HY, Cho HK, Kim KH and Cheong
J: The SDF-1alpha/CXCR4 axis induces the expression of fatty acid
synthase via sterol regulatory element-binding protein-1 activation
in cancer cells. Carcinogenesis. 31:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan B, Yau EX, Bte Omar SS, et al: A study
of HER2 gene amplification and protein expression in gastric
cancer. J Clin Pathol. 63:839–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grunt TW, Wagner R, Grusch M, et al:
Interaction between fatty acid synthase- and ErbB-systems in
ovarian cancer cells. Biochem Biophys Res Commun. 385:454–459.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oliveras G, Blancafort A, Urruticoechea A,
et al: Novel anti-fatty acid synthase compounds with anti-cancer
activity in HER2+ breast cancer. Ann N Y Acad Sci. 1210:86–92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin Q, Yuan LX, Boulbes D, et al: Fatty
acid synthase phosphorylation: A novel therapeutic target in
HER2-overexpressing breast cancer cells. Breast Cancer Res.
12:R962010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Silva SD, Perez DE, Alves FA, et al: ErbB2
and fatty acid synthase (FAS) expression in 102 squamous cell
carcinomas of the tongue: Correlation with clinical outcomes. Oral
Oncol. 44:484–490. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rice TW, Blackstone EH and Rusch VW: 7th
edition of the AJCC Cancer Staging Manual: Esophagus and
Esophagogastric Junction. Ann Surg Oncol. 17:1721–1724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Washington K: 7th edition of the AJCC
Cancer Staging Manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weiss SW: Franz M. Enzinger: His life and
work. Adv Anat Pathol. 13:109–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kindblom LG: Lipomatous tumours - how we
have reached our present views, what controversies remain and why
we still face diagnostic problems: A tribute to Dr Franz Enzinger.
Adv Anat Pathol. 13:279–285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ajana JA, Bathel JS, BekaiiSaab T, et al:
Gastric cancer. J Natl Compr Canc Netw. 8:378–409. 2010.PubMed/NCBI
|
|
29
|
Vandhana S, Deepa PR, Jayanthi U, Biswas J
and Krishnakumar S: Clinico-pathological correlations of fatty acid
synthase expression in retinoblastoma: An Indian cohort study. Exp
Mol Pathol. 90:29–37. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chung KY, Shia J, Kemeny NE, et al:
Cetuximab shows activity in colorectal cancer patients with tumors
that do not express the epidermal growth factor receptor by
immunohistochemistry. J Clin Oncol. 23:1803–1810. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shah MA, Jhawer M, Ilson DH, et al: Phase
II study of modified docetaxel, cisplatin, and fluororacil with
bevacizymab in patients with metastatic gastroesophageal
adenocarcinoma. J Clin Oncol. 23:1803–1810. 2005.PubMed/NCBI
|
|
32
|
Shah MA, Power DG, Kindler HL, et al: A
multicenter, phase II study of bortezomib (PS-341) in patients with
unresectable or metastatic gastric and gastroesophageal junction
adenomcarcinoma. Invest New Drugs. 29:1475–1481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Doi T, Muro K, Boku N, et al: Multicenter
phase II study of everolimus in patients with previously treated
metastatic gastric cancer. J Clin Oncol. 28:1904–1910. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gabrielson EW, Pinn ML, Testa JR and
Kuhajda FP: Increased fatty acid synthase is a therapeutic target
in mesothelioma. Clin Cancer Res. 7:153–157. 2001.PubMed/NCBI
|
|
35
|
Orita H, Coulter J, Tully E, et al: High
levels of fatty acid synthase expression in esophageal cancers
represent a potential target for therapy. Cancer Biol Ther.
10:549–554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kearney KE, Pretlow TG and Pretlow TP:
Increased expression of fatty acid synthase in human aberrant crypt
foci: Possible target for colorectal cancer prevention. Int J
Cancer. 125:249–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Visca P, Sebastiani V, Botti C, et al:
Fatty acid synthase (FAS) is a marker of increased risk of
recurrence in lung carcinoma. Anticancer Res. 24:4169–4173.
2004.PubMed/NCBI
|
|
38
|
Kapur P, Rakheja D, Roy LC and Hoang MP:
Fatty acid synthase expression in cutaneous melanocytic neoplasms.
Mod Pathol. 18:1107–1112. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kusakabe T, Nashimoto A, Honma K and
Suzuki T: Fatty acid synthase is highly expressed in carcinoma,
adenoma and in regenerative epithelium and intestinal metaplasia of
the stomach. Histopathology. 40:71–79. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dowling S, Cox J and Cenedella RJ:
Inhibition of fatty acid synthase by Orlistat accelerates gastric
tumor cell apoptosis in culture and increases survival rates in
gastric tumor bearing mice in vivo. Lipids. 44:489–498. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Allgayer H, Babic R, Gruetzner KU,
Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent
prognostic relevance in gastric cancer and is associated with the
expression of tumor-associated protease systems. J Clin Oncol.
18:2201–2209. 2000.PubMed/NCBI
|
|
42
|
Matsubara J, Yamada Y, Hirashima Y, et al:
Impact of insulin-like growth factor type 1 receptor, epidermal
growth factor receptor, and HER2 expressions on outcomes of
patients with gastric cancer. Clin Cancer Res. 14:3022–3029. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grabsch H, Sivakumar S, Gray S, Gabbert HE
and Müller W: HER2 expression in gastric cancer: Rare,
heterogeneous and of no prognostic value - conclusions from 924
cases of two independent series. Cell Oncol. 32:57–65.
2010.PubMed/NCBI
|
|
44
|
Kim KC, Koh YW, Chang HM, et al:
Evaluation of HER2 protein expression in gastric carcinomas:
Comparative analysis of 1,414 cases of whole-tissue sections and
595 cases of tissue microarrays. Ann Surg Oncol. 18:2833–2840.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
KumarSinha C, Ignatoski KW, Lippman ME,
Ethier SP and Chinnaiyan AM: Transcriptome analysis of HER2 reveals
a molecular connection to fatty acid synthesis. Cancer Res.
63:132–139. 2003.PubMed/NCBI
|
|
46
|
VazquezMartin A, FernandezReal JM,
OliverasFerraros C, et al: Fatty acid synthase activity regulates
HER2 extracellular domain shedding into the circulation of
HER2-positive metastatic breast cancer patients. Int J Oncol.
35:1369–1376. 2009.PubMed/NCBI
|
|
47
|
VazquezMartin A, Colomer R, Brunet J, Lupu
R and Menendez JA: Overexpression of fatty acid synthase gene
activates HER1/HER2 tyrosine kinase receptors in human breast
epithelial cells. Cell Prolif. 41:59–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Silva SD, Cunha IW, Rangel AL, et al:
Differential expression of fatty acid synthase (FAS) and ErbB2 in
nonmalignant and malignant oral keratinocytes. Virchows Arch.
453:57–67. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Menendez JA, Papadimitropoulou A, Vellon L
and Lupu R: A genomic explanation connecting ‘Mediterranean diet’,
olive oil and cancer: Oleic acid, the main monounsaturated fatty
acid of olive oil, induces formation of inhibitory ‘PEA3
transcription factor-PEA3 DNA binding site’ complexes at the
Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach
cancer cells. Eur J Cancer. 42:2425–2432. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin JT, Wu MS, Shun CT, Lee WJ, Sheu JC
and Wang TH: Occurrence of microsatellite instability in gastric
carcinoma is associated with enhanced expression of erbB-2
oncoprotein. Cancer Res. 55:1428–1430. 1995.PubMed/NCBI
|
|
51
|
Wu MS, Shun CT, Wang HP, et al: Genetic
alterations in gastric cancer: Relation to histological subtypes,
tumor stage, and Helicobacter pylori infection.
Gastroenterology. 112:1457–1465. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Polkowski W, van Sandick JW, Offerhaus GJ,
et al: Prognostic value of Laurén classification and c-erbB-2
oncogene overexpression in adenocarcinoma of the esophagus and
gastroesophageal junction. Ann Surg Oncol. 6:290–297. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lemoine NR, Jain S, Silvestre F, et al:
Amplification and overexpression of the EGF receptor and c-erbB-2
proto-oncogenes in human stomach cancer. Br J Cancer. 64:79–83.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tanner M, Hollmén M, Junttila TT, et al:
Amplification of HER-2 in gastric carcinoma: Association with
Topoisomerase IIalpha gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Alli PM, Pinn ML, Jaffee EM, McFadden JM
and Kuhajda FP: Fatty acid synthase inhibitors are
chemopreventative for mammary cancer in neu-N transgenic mice.
Oncogene. 24:39–46. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
DeVita F, Giuliani F, Silvestris N,
Catalano G, Ciardiello F and Orditura M: Human epidermal growth
factor receptor 2 (HER2) in gastric cancer: A new therapeutic
target. Cancer Treat Rev. 36 Suppl 3:S11–S15. 2010. View Article : Google Scholar
|
|
58
|
Lee KE, Lee HJ, Kim YH, et al: Prognostic
significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn
J Clin Oncol. 33:173–179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yu GZ, Chen Y and Wang JJ: Overexpression
of Grb2/HER2 signaling in Chinese gastric cancer: Their
relationship with clinicopathological parameters and prognostic
significance. J Cancer Res Clin Oncol. 135:1331–1339. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Park DI, Yun JW, Park JH, et al: HER-2/neu
amplification is an independent prognostic factor in gastric
cancer. Dig Dis Sci. 51:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Begnami MD, Fukuda E, Fregnani JH, et al:
Prognostic implications of altered human epidermal growth factor
receptors (HERs) in gastric carcinomas: HER2 and HER3 are
predictors of poor outcome. J Clin Oncol. 29:3030–3036. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pauletti G, Godolphin W, Press MF and
Slamon DJ: Detection and quantitation of HER-2/neu gene
amplification in human breast cancer archival material using
fluorescence in situ hybridization. Oncogene. 13:63–72.
1996.PubMed/NCBI
|
|
63
|
Hochwald SN, Kim S, Klimstra DS, Brennan
MF and Karpeh MS: Analysis of 154 actual five-year survivors of
gastric cancer. J Gastrointest Surg. 4:520–525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Takahiro T, Shinichi K and Toshimitsu S:
Expression of fatty acid synthase as a prognostic indicator in soft
tissue sarcomas. Clin Cancer Res. 9:2204–2212. 2003.PubMed/NCBI
|
|
65
|
Migita T, Ruiz S, Fornari A, et al: Fatty
acid synthase: A metabolic enzyme and candidate oncogene in
prostate cancer. J Natl Cancer Inst. 101:519–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lan KH, Lu CH and Yu D: Mechanisms of
trastuzumab resistance and their clinical implications. Ann N Y
Acad Sci. 1059:70–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nahta R, Yu D, Hung MC, Hortobagyi GN and
Esteva FJ: Mechanisms of disease: Understanding resistance to
HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol.
3:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nahta R and Esteva FJ: Herceptin:
Mechanisms of action and resistance. Cancer Lett. 232:123–138.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hortobagyi GN: Trastuzumab in the
treatment of breast cancer. N Engl J Med. 353:1734–1736. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
VazquezMartin A, Colomer R, Brunet J and
Menendez JA: Pharmacological blockade of fatty acid synthase (FASN)
reverses acquired autoresistance to trastuzumab (Herceptin by
transcriptionally inhibiting ‘HER2 super-expression’ occurring in
high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Int J Oncol. 31:769–776. 2007.PubMed/NCBI
|
|
71
|
Menendez JA, Vellon L and Lupu R:
Targeting fatty acid synthase-driven lipid rafts: A novel strategy
to overcome trastuzumab resistance in breast cancer cells. Med
Hypotheses. 64:997–1001. 2005. View Article : Google Scholar : PubMed/NCBI
|
